Differential immunomodulatory effects of epirubicin/cyclophosphamide and docetaxel in breast cancer patients
Kerstin Wimmer(Comprehensive Cancer Center Vienna), Florian Fitzal, Zsuzsanna Bagó-Horváth(Comprehensive Cancer Center Vienna), Christine Brostjan(Medical University of Vienna), Michael Gnant(Austrian Breast & Colorectal Cancer Study Group), Martin Filipits(University of Vienna), Rupert Bartsch(Universitätszahnklinik Wien), Daniel Egle(Innsbruck Medical University), Margaretha Rudas(Comprehensive Cancer Center Vienna), Hanna Birnleitner(Comprehensive Cancer Center Vienna), Ruth Exner(Comprehensive Cancer Center Vienna), Sophie Frantal(Statistics Austria), Cristiano Ramos(Instituto Português de Oncologia de Coimbra Francisco Gentil), Monika Sachet(Comprehensive Cancer Center Vienna), Rudolf Oehler(Medical University of Vienna), Marija Balić(University of Pittsburgh), Christian F. Singer(Comprehensive Cancer Center Vienna)
Cited by 18
Related Papers
Breast cancer
|Nature Reviews Disease Primers|2019|2.9k
Breast cancer
|The Lancet|2016|2.3k
Tailoring therapies—improving the management of early breast cancer: St Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2015
|Annals of Oncology|2015|1.8k
ESMO Clinical Practice Guideline for the diagnosis, staging and treatment of patients with metastatic breast cancer
|Annals of Oncology|2021|1.4k